Large-scale clinical studies for idiopathic pulmonary fibrosis (IPF) have focused primarily on TGF-β and associated signaling pathways, however, most of the clinical trial evidence suggests that therapies for IPF are only partially beneficial (3). The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.